Supplementary Figure 1 from Antagonism of SET Using OP449 Enhances the Efficacy of Tyrosine Kinase Inhibitors and Overcomes Drug Resistance in Myeloid Leukemia
crossref(2023)
摘要
PDF file - 66KB, OP449 in combination with ABL1 tyrosine kinase inhibitors inhibits BCR-ABL1 signaling in CML cells and cellular growth of primary CML blastic phase cells ex vivo.
查看译文
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络
Chat Paper
正在生成论文摘要